<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366470</url>
  </required_header>
  <id_info>
    <org_study_id>TB-VitaminD</org_study_id>
    <secondary_id>CTRI/2007/091/000008</secondary_id>
    <nct_id>NCT00366470</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients</brief_title>
  <official_title>A Double Blind, Randomized, Parallel, Placebo Control Design Study to Determine the Effect of Addition of Vitamin D to Conventional Anti TB Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Daley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Christian Medical College, Vellore, India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is some evidence that supplemental Vitamin D may contribute to quicker recovery from TB
      when given in addition to normal TB therapy. This needs to be proven with a controlled
      clinical trial. People receiving Vitamin D with anti TB therapy will be compared against
      people receiving anti TB therapy alone to see if vitamin D contributes to a quicker recovery
      (as shown by a quicker sputum culture conversion).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a parallel, randomized, double-blinded, placebo-controlled clinical
      trial to quantify the change, if any, in microbiological outcome in TB patients treated with
      vitamin D in combination with standard DOTS therapy. It will take place in four South Indian
      DOTS centres. The required sample size is 250 patients receiving ATT, to be randomised in a
      1:1 fashion (125 patients to receive vitamin D and 125 patients to receive placebo).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to sputum culture conversion</measure>
    <time_frame>8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Culture Positive</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Status</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Sputum Smear Conversion</measure>
    <time_frame>Continous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Smear Positive</measure>
    <time_frame>4 Weeks, 8 Weeks, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Growth In Liquid Media</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RNTCP Treatment Outcomes</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Gain</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D in doses of 100,000 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A. 100,000 IU Cholecalciferol per dose of 3.3ml</intervention_name>
    <description>100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>B. Migliol Oil without Cholecalciferol</intervention_name>
    <description>3.3 ml Migliol Oil, every two weeks for two months</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed smear positive pulmonary tuberculosis.

          2. Age between 18 to 75 years

          3. No pre-existing liver or renal disease

          4. Available for return visits as outlined in the trial protocol

          5. A Firm home address

        Exclusion Criteria:

          1. Extra-pulmonary or smear negative tuberculosis

          2. Patients receiving steroids, cytotoxic drugs, post transplant or metastatic
             malignancy, or not expected to survive for the duration of ATT

          3. Pregnant or lactating women

          4. Active diarrhoea, indicating possible fat-soluble vitamin malabsorption.

          5. Baseline Hypercalcemia &gt;10.5 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dilip Mathai, MD, FCAMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christian Medical College, Vellore, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Hospital</name>
      <address>
        <city>Ambur</city>
        <state>Tamilnadu</state>
        <zip>635 802</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2006</study_first_posted>
  <last_update_submitted>July 4, 2012</last_update_submitted>
  <last_update_submitted_qc>July 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Christian Medical College, Vellore, India</investigator_affiliation>
    <investigator_full_name>Peter Daley</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

